Product Description
Mechanisms of Action: PPAR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Korea
Approved Indications: None
Known Adverse Events: None
Company: Chong Kun Dang
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Korea
Active Clinical Trial Count: 3
Highest Development Phases
Phase 1: Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
A101_05BE2315 | P1 |
Completed |
Type 2 Diabetes |
2024-04-29 |
|
A101_03BE2112 | P1 |
Completed |
Type 2 Diabetes |
2023-07-23 |
50% |
A101_03BE2112 | P1 |
Completed |
Type 2 Diabetes |
2023-07-23 |
50% |
A101_03BE2112 | P1 |
Completed |
Type 2 Diabetes |
2023-07-23 |
50% |
A101_03BE2112 | P1 |
Completed |
Type 2 Diabetes |
2023-07-23 |
50% |
A101_04BE2113 | P1 |
Completed |
Type 2 Diabetes |
2023-06-04 |
50% |
A101_04BE2113 | P1 |
Completed |
Type 2 Diabetes |
2023-06-04 |
50% |
A101_04BE2113 | P1 |
Completed |
Type 2 Diabetes |
2023-06-04 |
50% |